Manufacturer
RANBAXY LABORATORIES LIMITED
Contents
Irbesartan 300mg + Hydrochlorothiazide 25mg
Indication
Hypertension
Instruction
May be taken with or without food.
Drug interaction
May increase serum lithium levels and toxicity. Enhanced hypotensive effect w/ other antihypertensive agents and barbiturates. Increased risk of hyperkalaemia w/ K-sparing diuretics, K supplements, or K-containing salt substitutes. Increased risk of symptomatic hyponatremia w/ carbamazepine. Irbesartan may cause acute renal failure w/ NSAIDs. Impaired absorption of hydrochlorothiazide w/ bile acid sequesterants (e.g. cholestyramine, colestipol). Hydrochlorothiazide may potentiate the effect of nondepolarising skeletal muscle relaxants (e.g. tubocurarine). Hydrochlorothiazide may enhance the hypercalcaemic effect of fat-soluble vit, folate, and Fe. Hydrochlorothiazide may increase electrolyte depletion, particularly hypokalaemia, when used w/ corticosteroids and ACTH. Thiazides may reduce the excretion of cytotoxic agents (e.g. cyclophosphamide, methotrexate) and potentiate their myelosuppressive effects. Thiazides may enhance the hyperglycaemic effect of β-blockers and diazoxide. Increased bioavailability of thiazides w/ anticholinergic agents (e.g. atropine, biperiden). Potentially Fatal: Increased risk of hypotension, hyperkalaemia, and decreased renal function (e.g. acute renal failure) when concomitantly used w/ aliskiren esp in patients w/ DM or renal impairment.
Malaysia
